BD Handed US FDA Warning Letter In Lead-Test Investigation
Executive Summary
The agency letter cites quality systems, Medical Device Reporting and device clearance concerns. It stems from an ongoing investigation into lead tests distributed by Magellan Biosciences that sometimes give faulty results.
You may also be interested in...
US FDA: Bad Lead Test Results Tied To Test-Tube Stopper Chemical
An investigation by FDA and BD has concluded that a chemical used in some test-tube stoppers is the reason for false results on some blood-based lead tests from Magellan Diagnostics.
Warning Letter Roundup & Recap – Jan. 16, 2018
Becton Dickinson received a scathing missive from US FDA that addresses quality systems, Medical Device Reporting and pre-market violations at the firm's Franklin Lakes, NJ, facility. It was the only device-related warning letter released by the agency this week.
US FDA: BD Didn't Document Faulty Lead-Test Warning
An FDA-483 released as part of an ongoing probe into Magellen’s faulty LeadCare tests found potential GMP and Medical Device Reporting violations at a BD location.